Rare, aggressive, and uniformly fatal, diffuse intrinsic pontine glioma (DIPG) is a pediatric brain cancer with no known effective treatment. Children with DIPG rarely live 2 years past diagnosis.
In collaboration, there is hope. A group of researchers, including Charles River’s medicinal chemistry team and Meds4Kids, have identified and developed a lead compound with excellent profiles, high oral bioavailability, and effective brain penetration in preliminary studies. Currently progressing to proof-of-concept, this potentially life-saving compound is the fruit of an open science approach to drug development.
View our 30-minute webinar to learn how the collective knowledge, regulatory data protections, and market incentives of the open science framework can advance the development of treatments for DIPG and other rare diseases.
Team Leader, Chemistry, Charles River